Some stocks fly under the radar of investors even as they quietly dominate the industry in which they operate. These stealth stocks rise to the top by developing competitive advantages. This allows them to take market share from competitors and deliver strong financial results. Wall Street analysts who cover specific economic sectors and their competing stocks might notice the dominance of a particular company. However, retail investors often miss out. Lack of media coverage and attention to certain stocks allows them to slip by unnoticed. And this can happen even as their share price steadily rises. Let’s explore three such hot stocks that could surely dominate their sectors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corning (GLW) the corning (GLW) logo and homepage displayed on a mobile phone Source: madamF / Shutterstock.com Specialty glassmaker Corning (NYSE:GLW) doesn’t get much attention. But its shares are up 12% on the day of this writing after the company raised its forward guidance ahead of its Q2 financial results to be released on July 30. Corning said that it expects revenue of $3.6 billion compared with previous guidance that had called for $3.4 billion in Q2 sales. In terms of profit, Corning is now forecasting EPS at the “high end” of its range of 42 cents to 46 cents. Corning added that it is seeing increased sales as demand rises for its new optical connectivity products designed for artificial intelligence (AI). While still best known for its CorningWare line of cookware, the company divested that consumer products business back in 1998. Today, Corning is a tech company that makes specialty glass that’s used for technological and scientific applications. In practical terms, Corning makes glass for big-screen TVs, mobile phones such as Apple’s (NASDAQ:AAPL) iPhone and fiber optics. GLW stock is now up 41% on the year. Eli Lilly (LLY) Eli Lilly (LLY) sign on corporate building with blue sky in background Source: shutterstock.com/Michael Vi If Eli Lilly & Co. (NYSE:LLY) doesn’t already dominate the pharmaceutical industry, it looks like it will in short order. Since July 1, the company has received regulatory approval from the U.S. Food and Drug Administration (FDA) to begin selling its Alzheimer medication that is expected to be a blockbuster drug. Also, LLY announced that it is buying biopharmaceutical companyMorphic Holding (NASDAQ:MORF) for $3.2 billion. Morphic Holding develops treatments for chronic diseases, specifically inflammatory bowel disease. The deal is expected to help Eli Lilly expand further into the gastroenterology medical specialty. Last fall, the FDA approved Eli Lilly’s drug “Omvoh,” which is used to treat ulcerative colitis. Approval of the Alzheimer drug, called “Donanemab,” and the Morphic purchase come as Eli Lilly is struggling to meet global demand for its weight loss drug “Zepbound,” another blockbuster medication. Given all the positive developments, it should come as no surprise that LLY stock has risen 102% over the last 12 months, making it among the best performing pharma stocks. UBS (UBS) Smartphone with Credit Suisse Bank (CS) logo on background of UBS Bank symbol blurred, Switzerland, March 18, 2023 Source: Below the Sky / Shutterstock.com In the banking sector, Swiss financial giant UBS Group (NYSE:UBS) looks to have a more dominant position after completing its merger with former rival Credit Suisse on July 1. UBS agreed to acquire Credit Suisse in 2023 for $3.2 billion after that bank’s failure. The takeover of Credit Suisse has left Switzerland, arguably the world’s best known banking center, with one global bank that has a balance sheet twice as large as the country’s economy. If nothing else, the absorption of Credit Suisse gives UBS sufficient size to better compete against major international lenders such as JPMorgan Chase (NYSE:JPM) in the U.S. and HSBC Holdings (NYSE:HSBC) in the U.K. Also, the deal’s completion gives UBS a near monopoly position as the only full-service depository bank in its home country of Switzerland, whose population is just under nine million people. UBS stock has risen 52% in the last 12 months. On the date of publication, Joel Baglole held a long position in LLY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia. More From InvestorPlace Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors appeared first on InvestorPlace.
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...